The expected total costs were NTD 389,375 with PEG and NTD 232,382 with LAM (difference NTD 156,992).
The expected LYs were 11.45 with PEG and 11.07 with LAM (difference 0.38).
The QALYs were 10.57 with PEG and 10.12 with LAM (differences 0.45).
The incremental cost per LY gained with PEG was NTD 413,770.
The incremental cost per QALY gained with PEG was NTD 346,868 (95% CI: 228,000 to 566,000), or $10,900 (95% CI: 7,100 to 17,700).
The deterministic sensitivity analysis showed that the most influential model inputs were the relapse rate after PEG was stopped, the probability of developing compensated cirrhosis from CHB, and the relapse rate after LAM treatment was stopped. Nevertheless, the incremental cost per QALY did not exceed the value of NTD 448,000, regardless of the variations performed in the analysis.
The probabilistic sensitivity analysis showed that the value put on a QALY should have been less than NTD 350,000 ($11,100) before the probability of PEG being cost-effective fell below 50%.